AGTR1 and neoplasm: An additional immune-based strategy aims to reshape/reprogram immunosuppressive TME and tumor-promoting stroma into an immune-activated state, for example, by reprogramming protumor TAM-2 into antitumor TAM-1 (3), or targeting CAFs as attempted by dual targeting of CAFs and tumor cells through angiotensin II type I receptor (AT1R) overexpressed on both CAFs and tumor cells using pathological inspired micelles (74).